uniQure Schedules Key FDA Type A Meeting for AMT-130 Accelerated Approval Pathway
QURE has more than doubled off its 52-week low of $7.76.
Summary
uniQure N.V. announced a Type A meeting with the FDA has been scheduled to discuss the Biologics License Application (BLA) data package to support accelerated approval of its Huntington's disease gene therapy, AMT-130.
Key Events · Product Development and Regulatory · QURE
-
FDA Type A Meeting Scheduled
uniQure N.V. has scheduled a Type A meeting with the U.S. Food and Drug Administration (FDA).
-
Discussion for AMT-130 Accelerated Approval
The meeting will focus on the Biologics License Application (BLA) data package to support accelerated approval of AMT-130, an investigational gene therapy for Huntington's disease.
-
CEO Emphasizes Timely Resolution
CEO Matt Kapusta expressed anticipation for a constructive discussion with the FDA to achieve a timely resolution regarding the accelerated approval pathway for AMT-130.
-
Regulatory Update Expected
The company plans to provide a regulatory update following the receipt of official meeting minutes from the FDA.
Analysis · QURE · Life Sciences
This announcement signals a critical regulatory milestone for uniQure's lead gene therapy candidate, AMT-130, for Huntington's disease. A Type A meeting with the FDA is a high-stakes discussion, typically held to resolve significant issues or to define the path forward for a Biologics License Application (BLA), especially when seeking accelerated approval. The outcome of this meeting will provide crucial clarity on the FDA's perspective regarding the BLA data package and the potential for an accelerated approval pathway. Investors should monitor for the company's subsequent regulatory update, as it will directly impact the timeline and commercial prospects of this important pipeline asset.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QURE was trading at $24.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.76 to $71.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.